Detalles de la búsqueda
1.
Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes.
Diabetologia
; 67(1): 3-18, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37801140
2.
Supporting the 'lived expertise' of older adults with type 1 diabetes: An applied focus group analysis to characterize barriers, facilitators, and strategies for self-management in a growing and understudied population.
Diabet Med
; 41(1): e15156, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37278610
3.
Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial.
Diabetes Obes Metab
; 26(5): 1714-1722, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38317618
4.
Associations of Dietary Intake with the Intestinal Microbiota and Short-Chain Fatty Acids Among Young Adults with Type 1 Diabetes and Overweight or Obesity.
J Nutr
; 153(4): 1178-1188, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36841667
5.
Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium-glucose cotransporter-2 inhibitor ertugliflozin.
Diabetes Obes Metab
; 25(3): 758-766, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36394384
6.
Weight management in young adults with type 1 diabetes: The advancing care for type 1 diabetes and obesity network sequential multiple assignment randomized trial pilot results.
Diabetes Obes Metab
; 25(3): 688-699, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36314293
7.
Associations of disordered eating with the intestinal microbiota and short-chain fatty acids among young adults with type 1 diabetes.
Nutr Metab Cardiovasc Dis
; 33(2): 388-398, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36586772
8.
A Novel Endocrine Role for the BAT-Released Lipokine 12,13-diHOME to Mediate Cardiac Function.
Circulation
; 143(2): 145-159, 2021 01 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33106031
9.
A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes.
Rev Endocr Metab Disord
; 23(5): 979-994, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35838946
10.
Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial.
Am J Nephrol
; 53(7): 516-525, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35691283
11.
Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV.
Diabetes Obes Metab
; 24(7): 1245-1254, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35266296
12.
The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV.
Diabetes Obes Metab
; 24(6): 1114-1122, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35233908
13.
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus.
Diabetes Obes Metab
; 24(9): 1829-1839, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35603908
14.
Proteomics and Phosphoproteomics of Circulating Extracellular Vesicles Provide New Insights into Diabetes Pathobiology.
Int J Mol Sci
; 23(10)2022 May 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-35628588
15.
Twenty-four hour assessments of substrate oxidation reveal differences in metabolic flexibility in type 2 diabetes that are improved with aerobic training.
Diabetologia
; 64(10): 2322-2333, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34402932
16.
An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg.
Diabetes Obes Metab
; 23(11): 2513-2520, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34286894
17.
Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis.
Diabetes Obes Metab
; 23(9): 2058-2066, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34009708
18.
Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial.
Diabetes Obes Metab
; 23(2): 569-580, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33185002
19.
Cardiovascular Outcome Trials with Glucose-Lowering Drugs.
Curr Cardiol Rep
; 23(7): 75, 2021 06 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34081215
20.
Cardiovascular Outcomes Trials of Incretin-Based Therapies.
Diabetes Spectr
; 34(3): 217-224, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34511847